Cormac Sheridan
#162,372
Most Influential Person Now
Cormac Sheridan's AcademicInfluence.com Rankings
Cormac Sheridanbiology Degrees
Biology
#12946
World Rank
#16455
Historical Rank
Biotechnology
#231
World Rank
#233
Historical Rank
Download Badge
Biology
Cormac Sheridan's Degrees
- Bachelors Biochemistry National University of Ireland
- Masters Biotechnology National University of Ireland
Why Is Cormac Sheridan Influential?
(Suggest an Edit or Addition)Cormac Sheridan's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Gene therapy finds its niche (2011) (319)
- Fast, portable tests come online to curb coronavirus pandemic (2020) (277)
- Exosome cancer diagnostic reaches market (2016) (136)
- Coronavirus and the race to distribute reliable diagnostics (2020) (128)
- First Axl inhibitor enters clinical trials (2013) (93)
- IDO inhibitors move center stage in immuno-oncology (2015) (86)
- Proof of concept for next-generation nanoparticle drugs in humans (2012) (68)
- New Merck and Vertex drugs raise standard of care in hepatitis C (2011) (56)
- Fresh from the biologic pipeline—2009 (2010) (48)
- TeGenero fiasco prompts regulatory rethink (2006) (45)
- Convalescent serum lines up as first-choice treatment for coronavirus (2020) (45)
- Drug developers switch gears to inhibit STING (2019) (42)
- COVID-19 spurs wave of innovative diagnostics (2020) (38)
- FDA approves 'farmaceutical' drug from transgenic chickens (2016) (34)
- First approval in sight for Novartis' CAR-T therapy after panel vote (2017) (34)
- Illumina claims $1,000 genome win (2014) (33)
- Amgen's bispecific antibody puffs across finish line (2015) (32)
- Making green (2009) (31)
- First oncolytic virus edges towards approval in surprise vote (2015) (30)
- Pancreatic cancer provides testbed for first mechanotherapeutics (2019) (30)
- Recasting natural product research (2012) (27)
- Pharma consolidates its grip on post-antibody landscape (2007) (27)
- FDA approvals usher in the post-interferon era in HCV (2014) (27)
- Sangamo's landmark genome editing trial gets mixed reception (2018) (27)
- The business of making vaccines (2005) (25)
- EPO neem patent revocation revives biopiracy debate (2005) (25)
- Ablynx's nanobody fragments go places antibodies cannot (2017) (24)
- First off-the-shelf mesenchymal stem cell therapy nears European approval (2018) (24)
- Coronavirus testing finally gathers speed. (2020) (23)
- Big oil turns on biofuels (2013) (23)
- Cardiac stem cell therapies inch toward clinical litmus test (2013) (23)
- First-in-class cancer therapeutic to stimulate natural killer cells. (2006) (23)
- Amgen announces oncolytic virus shrinks tumors (2013) (21)
- Milestone approval lifts Illumina's NGS from research into clinic (2014) (21)
- Antibiotics au naturel (2006) (21)
- Death by inflammation: drug makers chase the master controller (2019) (19)
- Go-ahead for first in-body CRISPR medicine testing (2018) (19)
- CRISPR therapeutics push into human testing (2017) (19)
- Tysabri raises alarm bells on drug class (2005) (19)
- Investors keep the faith in cancer liquid biopsies (2019) (19)
- Protein chip companies turn to biomarkers (2005) (19)
- Despite slow progress, bispecifics generate buzz (2016) (18)
- First COVID-19 DNA vaccine approved, others in hot pursuit (2021) (17)
- SGLT2 inhibitors race to enter type-2 diabetes market (2012) (17)
- A taste of the future (2004) (16)
- Phase 3 data for PCSK9 inhibitor wows (2013) (16)
- First small-molecule drug targeting RNA gains momentum (2021) (15)
- Small molecule challenges dominance of TNF-α inhibitors (2008) (15)
- First CRISPR-Cas patent opens race to stake out intellectual property (2014) (15)
- Grail of RAS cancer drugs within reach (2020) (15)
- Commercial interest grows in glycan analysis (2007) (15)
- Bispecific antibodies poised to deliver wave of cancer therapies (2021) (15)
- Kenyan dispute illuminates bioprospecting difficulties (2004) (14)
- Towards the development of a wearable rehabilitation device for stroke survivors (2009) (13)
- Footrace to clinic heats up for T-cell nuclear receptor inhibitors (2013) (13)
- J&J's billion dollar punt on anti-amyloid antibody (2009) (13)
- Doubts surround link between Bt cotton failure and farmer suicide (2009) (13)
- COVID-19 testing turns to T cells (2021) (13)
- Cautious optimism surrounds early clinical data for PD-1 blocker (2012) (12)
- Pivotal trials for β-secretase inhibitors in Alzheimer's (2015) (12)
- Doubts raised over 'read-through' Duchenne drug mechanism (2013) (12)
- Industry continues dabbling with open innovation models (2011) (12)
- Genentech to salvage anti-MET antibody with subgroup analysis (2014) (12)
- A novel wrist rehabilitation/assistive device (2009) (12)
- Immune-checkpoint inhibitors march on, now in combinations (2014) (12)
- Calamitous HCV trial casts shadow over nucleoside drugs (2012) (11)
- Amgen's angiopoietin blocker fails in ovarian cancer (2015) (11)
- Drug makers target ubiquitin proteasome pathway anew (2015) (11)
- Genentech raises stakes on PARP inhibitors (2006) (10)
- Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare (2021) (10)
- EGFR inhibitors embrace KRAS (2008) (10)
- Wnt is back in drugmakers' sights, but is it druggable? (2018) (10)
- PCSK9-gene-silencing, cholesterol-lowering drug impresses (2019) (10)
- Europe lags, US leads 2nd-generation biofuels (2008) (9)
- Genentech obtains proof of concept for hedgehog inhibition (2009) (9)
- Vaccine market boosters (2009) (9)
- Apple moves on health, drug developers shift into smart gear (2014) (9)
- Cancer centers zero in on exceptional responders (2014) (9)
- Report claims no yield advantage for Bt crops (2009) (9)
- Bad medicine (2007) (9)
- CETP inhibitors boost 'good' cholesterol to no avail (2016) (9)
- Questions swirl around failures of disease-modifying Huntington’s drugs (2021) (9)
- Billion-dollar deal propels RNAi to CNS frontier (2019) (8)
- Biotrin assay to monitor cervical cancer exposure rates (2007) (8)
- Drugmakers cling to dual IL-13/IL-4 blockbuster hopes (2018) (8)
- Companies in rapid pursuit of Btk immunokinase (2012) (8)
- CRISPR germline editing reverberates through biotech industry (2015) (8)
- Erratum: Gene therapy finds its niche (2011) (8)
- With Alnylam's amyloidosis success, RNAi approval hopes soar (2017) (8)
- Nature Biotechnology's academic spinouts of 2016 (2017) (8)
- Antiinfective biotechs face partnering gap (2005) (8)
- Nature Biotechnology’s academic spinouts of 2018 (2019) (7)
- Industry pursues co-stimulatory receptor immunomodulators to treat cancer (2013) (7)
- Third oral MS drug wins FDA nod (2013) (7)
- Immuno-oncology moves beyond PD-1 (2015) (7)
- It came from beneath the sea (2005) (7)
- FDA approves pertuzumab (2012) (7)
- New class PCSK9 blockers stride into cholesterol market (2015) (7)
- Grail to pour $1 billion into blood test to detect early cancer (2017) (7)
- EU to review rare disease drugs market exclusivity (2004) (7)
- Drug developers refocus efforts on RAS (2016) (7)
- Big oil's biomass play (2007) (7)
- Omics-driven startups challenge healthcare model (2015) (7)
- Stem cell therapy clears first hurdle in AMD (2014) (7)
- Gene therapy rescues newborns with spinal muscular atrophy (2018) (6)
- Amgen swallows Micromet to BiTE into ALL market (2012) (6)
- Seres's pioneering microbiome drug fails mid-stage trial (2016) (6)
- Massive data initiatives and AI provide testbed for pandemic forecasting (2020) (6)
- Anti-CD20 antibody wows in multiple sclerosis (2015) (6)
- First cystic fibrosis drug advances towards approval (2011) (6)
- Can 'double blockbuster' strengthen Amgen's backbone? (2008) (6)
- Next generation flu vaccine boosted by Chiron debacle (2004) (6)
- Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance (2016) (6)
- Oncologists greet Lumakras: the world’s first KRAS inhibitor (2021) (6)
- Fast track to MS drug (2004) (6)
- Insomniacs get new mechanism sleep drug Belsomra (2014) (5)
- Innovators target vaccines for variants and shortages in global South (2021) (5)
- Novartis trial validates inflammasome as chronic disease driver (2017) (5)
- Questions remain following first COVID-19 vaccine results. (2020) (5)
- Llama-inspired antibody fragment approved for rare blood disorder (2019) (5)
- A reprieve from hemophilia A, but for how long? (2020) (5)
- First new drug approval for AML in 15 years (2017) (5)
- CRISPR therapies march into clinic, but genotoxicity concerns linger (2021) (5)
- Cost-effectiveness data on biologics needed (2005) (5)
- Allogene and Celularity move CAR-T therapy off the shelf (2018) (5)
- Tysabri back on market (2006) (5)
- COVID-19 vaccine makers chase variant-ready vaccines (2022) (5)
- Amgen punts on deCODE's genetics know-how (2013) (4)
- CAR-T cells forge ahead, Novartis reorganizes (2016) (4)
- Flu vaccine makers upgrade technology—and pray for time (2009) (4)
- Big oil bucks for algae (2009) (4)
- First PD-1 inhibitor breezes across finish line (2014) (4)
- Roche backs Aileron's stapled peptides (2010) (4)
- Convalescent plasma falls flat in first randomized trial. (2020) (4)
- Glial cells on the radar (2009) (4)
- Stem cell controversy to stall European tissue and cell therapy rules (2006) (4)
- Positive clinical data in Parkinson's and ischemia buoy gene therapy (2007) (4)
- Genentech's Ocrevus heralds new chapter in MS treatment (2017) (4)
- RNA drugs lower lipoprotein(a) and genetically driven cholesterol (2022) (3)
- Low-molecular-weight albumin drug touted for severe osteoarthritis (2018) (3)
- First integrin inhibitor since Tysabri nears approval for IBD (2014) (3)
- Benefits of biotech clusters questioned (2003) (3)
- To win at gene therapy, companies pick viruses with production credentials (2019) (3)
- Hemophilia market awaits next-generation therapies (2011) (3)
- Safety profiles come to fore as more drugs approach MS market (2012) (3)
- Firms combine experimental cancer drugs to speed development (2010) (3)
- Investors start backing hearing loss treatments (2013) (3)
- Germany biotech gets second chance (2003) (3)
- Report blames GM crops for herbicide spike, downplays pesticide reductions (2010) (3)
- Mammoth, Arbor and Beam launch new wave of CRISPR startups (2018) (2)
- Biogen and UPenn join forces to commercialize gene therapies (2016) (2)
- Production technologies change flu vaccine landscape (2007) (2)
- Politics torpedo biotech as EU priority (2005) (2)
- Pertuzumab to bolster Roche/Genentech's breast cancer franchise? (2011) (2)
- Merck vaccine heads Ebola countermeasures (2018) (2)
- Cimzia's setback paves way for other TNF inhibitors in Crohn's disease (2007) (2)
- Monoclonal T-cell receptor drugs pique pharma's interest (2013) (2)
- CRISPR patent estate splinters (2017) (2)
- Synthetic biology firms pivot from biofuels to cheap biologics (2016) (2)
- Abbott outbids Biogen for Facet's multiple sclerosis antibody (2010) (2)
- Monster investment puts Baltimore on biotech startup map (2019) (2)
- mRNA printers kick-start personalized medicines for all (2022) (2)
- Chiron's manufacturing misfortunes boost competitors (2005) (2)
- Drugmakers turn sights on scarred lungs (2020) (2)
- Belgian biotech's clot-buster approved for aging eyes (2012) (1)
- EMEA struggles with need to restructure (2003) (1)
- Publisher Correction: First small-molecule drug targeting RNA gains momentum (2021) (1)
- Erratum: Nature Biotechnology's academic spinouts of 2016 (2017) (1)
- Correction: Corrigendum: Industry continues dabbling with open innovation models (2012) (1)
- Serono changes tack (2006) (1)
- Publisher Correction: Death by inflammation: drug makers chase the master controller (2019) (1)
- Who's who in biotech (2006) (1)
- For hemophilia and thalassemia, a new era of ‘one-and-done’ gene therapies has arrived (2022) (1)
- German biotech sector inches forward despite long odds. (2005) (1)
- Topical herpesvirus gene therapy enters final lap (2022) (1)
- Pfizer swallows Wyeth, validates niche buster (2009) (1)
- Gene editing enters 'prime' time. (2019) (1)
- RaNA Therapeutics (2012) (1)
- Rising biotech appetite in the East (2006) (1)
- Merck stakes out 'irritable' neuron territory with $1.25 billion (2016) (1)
- Cord blood cell therapy trial suspended (2005) (1)
- Surprise rejection for Amgen's D-peptide (2016) (1)
- Diversa restructures, raising question over bioprospecting (2006) (1)
- Unicorn startup trawls databases for protective genetic modifiers (2019) (1)
- Roche splashes $2.4 billion on Foundation Medicine's cancer platform (2018) (1)
- Huntington’s antisense drug marches into clinic (2020) (1)
- ScanBalt coordinates intellectual property in Northern Europe. (2004) (1)
- Firms chase diabetic inflammation with anti-IL-1β antibodies (2010) (1)
- Around the world in a month (2015) (0)
- Irish biotech buoyant (2009) (0)
- Novo sets sights on obesity market with diabetes drug (2014) (0)
- Erratum: Doubts surround link between Bt cotton failure and farmer suicide (2009) (0)
- Drug developers switch gears to inhibit STING (2019) (0)
- BioXell: an Italian biotech success story? (2006) (0)
- Will J&J turbocharge Crucell's vaccine portfolio? (2010) (0)
- Bluebird’s CALD gene therapy poised for approval (2022) (0)
- Industry appetite for natural killer cells intensifies (2023) (0)
- Sickle cell gene therapies approach watershed (2021) (0)
- COVID-19 spurs wave of innovative diagnostics (2020) (0)
- Publisher Correction: Questions swirl around failures of disease-modifying Huntington’s drugs (2021) (0)
- Publisher Correction: Oncologists greet Lumakras: the world’s first KRAS inhibitor (2021) (0)
- Unicorn startup trawls databases for protective genetic modifiers (2019) (0)
- Erratum: Who's who in biotech (2006) (0)
- COVID-19 vaccine makers chase variant-ready vaccines (2022) (0)
- Drugmakers use real-world patient data to calibrate product development (2011) (0)
- Grail of RAS cancer drugs within reach (2020) (0)
- Death by inflammation: drug makers chase the master controller (2019) (0)
- Publisher Correction: Death by inflammation: drug makers chase the master controller (2019) (0)
- Around the world in a month (2013) (0)
- National Academies relax stance on germline edits (2017) (0)
- 100,000 whole-genome sequences’ diagnostic bonus (2021) (0)
- The Same Old Future (2007) (0)
- CRISPR patent estate splinters (2017) (0)
- National Academies relax stance on germline edits (2017) (0)
- Celgene eyes 'inverse vaccines' in Anokion and Delinia deals (2017) (0)
- Publisher Correction: Questions swirl around failures of disease-modifying Huntington’s drugs (2021) (0)
- Drugmakers turn sights on scarred lungs (2020) (0)
- Around the world in a month (2019) (0)
- Interest rekindles in drug cocktails that reprogram cells (2017) (0)
- P55 Minimally invasive surgery in wire-guided breast biopsy: Role of specimen mammography in predicting margins (1998) (0)
- European pharma consolidation generates quality spinoffs (2006) (0)
- Living and dying with viruses (2005) (0)
- Erratum: Can 'double blockbuster' strengthen Amgen's backbone? (2008) (0)
- Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare (2021) (0)
- Corrigendum: Drugmakers use real-world patient data to calibrate product development (2012) (0)
- Erratum: Irish bioethics council axed (2010) (0)
- First Rounders: Bassil Dahiyat (2020) (0)
- Huntington’s antisense drug marches into clinic (2020) (0)
- First in class stimulates natural killer cells (2006) (0)
- Publisher Correction: Sickle cell gene therapies approach watershed (2021) (0)
- Interest heats up in gastrointestinal space (2006) (0)
- Spanish wishful thinking towards biotech. (2005) (0)
- Drugmakers plow more resources into autism (2013) (0)
- Around the world in a month (2020) (0)
- Billion-dollar deal propels RNAi to CNS frontier (2019) (0)
- Llama-inspired antibody fragment approved for rare blood disorder (2019) (0)
- First small-molecule drug targeting RNA gains momentum (2021) (0)
- Corrigendum: Industry pursues co-stimulatory receptor immunomodulators to treat cancer (2013) (0)
- FDA dictates on gene therapy sameness (2020) (0)
- Repairing the eye (2022) (0)
- Shoot the messenger: RNA editing is here (2023) (0)
- Irish bioethics council axed (2010) (0)
- Genetic medicines aim straight for the heart (2023) (0)
- New biotech oasis? (2005) (0)
This paper list is powered by the following services:
